Speaking at the PharmEvolution, the 3rd international forum on the development of pharmaceutical industry in Russia, Anatoly Artamonov, the Governor of the Kaluga region, said, “In 2016, the production growth in Kaluga pharmaceutical cluster was 37%. Combining efforts of pharmaceutical companies within the cluster can lead to amazing results. In five years, we will have a 10-12% share of the total production volume.”
The participants of the cluster intend to implement a number of significant projects. For example, Hemofarm and AstraZeneca Industries will take part in a pilot project on labeling individual medicinal products with control marks. Hemofarm will begin the construction of a new general laboratory block intended for localisation of its R&D unit in the Kaluga region. Pharm-Sintez will complete the construction of its microbiological laboratory to manufacture the medicinal products. The companies in the cluster will continue to register and launch the new medicines and medical devices. The plans include the opening of two production facilities, such as a plant of Pharm-Sintez to manufacture finished medicinal products and a plant of SANATMETAL CIS to manufacture the implants and medical devices.
Pharmaceutical companies of the region manufacture about 139 products and will add several dozen in the future. More than 80% of products manufactured in the cluster are finished medicines.